Close

Retrophin (RTRX) Presents New, Significant Data from Sparsentan Phase 2 as FSGS Treatment

Go back to Retrophin (RTRX) Presents New, Significant Data from Sparsentan Phase 2 as FSGS Treatment

Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016

November 19, 2016 1:10 PM EST

Significant reduction of proteinuria compared to irbesartan

Statistically significant difference in modified partial remission; complete remission also observed

Further analysis supports sparsentan generally safe and well-tolerated

SAN DIEGO, Nov. 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder without an FDA-approved pharmacologic treatment that often leads to end-stage renal disease. These new findings are being presented today in the... More